curriculum vitae ramón bataller, m.d.sph.unc.edu/files/2013/07/708770519_cv.pdf · endoscópico...

CURRICULUM VITAE

Ramón Bataller, M.D.

Personal Data:

Citizenship: Spain

Business Address: 2209 McGavran-Greenberg

University of North Carolina at Chapel Hill

C.B. # 7461

Chapel Hill, NC 27599-7461

Languages: Catalan, Spanish, English, Italian

Education:

High School: Colegio Maristas, Valencia, Spain

University of Valencia School of Medicine, Valencia, Spain, 1984-1990.

Professional Experience:

Resident, Liver and Gastroenterology Units, Hospital Clínic, Barcelona, 1991-1994.

Faculty member, Emergency Room, Hospital Clínic, Barcelona, 1994-1998.

Research Fellow, Liver Unit, Hospital Clínic, Barcelona, 1995-2000.

Visiting Fellow, Università degli Studi di Firence, Florence, Italy, 1995.

Visiting Fellow, Free University of Brussels, Brussels, Belgium, 1997.

Postdoctoral Fellow, University of North Carolina at Chapel Hill, 2000-2003.

Senior Especialist, Liver Unit, Hospital Clínic, Barcelona, 2003-2011

Associate Porfessor, UNC Chapel Hill, 2011-present

Board Certified:

Diplomate of Spanish Board of Gastroenterology, 1995.

Societies:

Member, Asociación Española para el Estudio del Hígado.

Member, European Association for the Study of Liver Diseases (EASL).

Member of the Scientific Committee, Governing Board, EASL (2009-2011)

Member, International Society for Research of Hepatic Sinosoid (ISRHS)

2

Editorial Board

Gastroenterology (2007-2010)

World Journal of Gastroenterology (2006-)

Gut (Associate Editor 2008-2011)

Gastroenterology Research and Practice (2009-)

Research Interests:

Pathogenesis and treatment of hepatic fibrosis.

Alcohol-induced liver disease.

Nonalcoholic steatohepatitis.

PUBLICATIONS

Original articles:

1.- Bataller Sifre R, Gómez García MA, Ferrandis Borrás S, Bataller R, Bataller Alberola RB y

Alberola García MD. Replicación viral, daño histológico y movimiento enzimático en

hepatopatías crónicas por virus B. Rev Esp Enf Digest 1989;6: 537-543.

2.- Bataller R, Llach J, Salmerón JM, Elizalde JI, Mas A, Piqué JM, Brullet E, Terés J, Bordas

JM, Rodés J. Endoscopic sclerotherapy in upper gastrointestinal bleeding due to the Mallory-

Weiss syndrome. Am J Gastroenterol 1994;89:112-116.

3.- Bataller Sifre R, Roselló Morera J, Bataller R, Ferrández Izquierdo A, Castillo Pallarés J,

Bort Martí J, Galindo Puerto MJ. Correlación del cociente hígado/bazo isotópico con el daño

hístico en hepatopatías crónicas difusas. Rev Esp Enf Digest 1994; 86:651-654.

4.- Elizalde JI, Llach J, Bordas JM, Bataller R, Mondelo F, Panés J, Terés J. Valor del control

endoscópico tras escleroterapia por lesión péptica gastroduodenal. Gastroenterol Hepatol

1994;17:11-13.

5.- Nieto I, Llach J, Bordas JM, Mondelo F, Elizalde JI, Bataller R, Terés J. Hallazgos

endoscópicos gastrointestinales en pacientes infectados por el virus de la inmunodeficiencia.

Gastroenterol Hepatol 1995;18:57-60.

6.- Saló J, Ginès A, Anibarro L, Jiménez W, Bataller R, Clària J, Ginès P, Rivera F, Arroyo V,

Rodés J. Effect of upright posture and physical exercise on endogenous neurohormonal

3

systems in cirrhotic patients with sodium retention and normal supine plasma renin,

aldosterone and norepinephrine levels. Hepatology 1995;22:479-487.

7.- Saló J, Ginès A, Quer JC, Planas R, Ginès P, Bataller R, Jiménez W, Fernández-

Esparrach G, Arroyo V, Rodés J. Renal and neurohormonal changes following simultaneous

administration of systemic vasoconstrictors and renal vasodilators in patients with hepatorenal

syndrome. J Hepatol 1996;25: 916-923.

8.- Saló J, Jiménez W, Kuhn M, Ginès A, Ginès P, Fernández-Esparrach G, Angeli P, Clària J,

Bataller R, Arroyo V, Forssmann WG, Rodés J. Urinary excretion of urodilatin in patients with

cirrhosis. Hepatology 1996;24:1428-1432.

9.- Saló J, Ginès A, Quer JC, Fernández-Esparrach G, Guevara M, Ginès P, Bataller R,

Planas R, Jiménez W, Arroyo V, Rodés J. Renal and neurohormonal changes following

simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in

cirrhotic patients with hepatorenal syndrome. J Hepatol 1996;25:916-923.

10.- Bordas JM, Elizalde I, Llach J, Mondelo F, Bataller R, Teres J. Biliary reflux due to

sphincter of Oddi ablation: a new pathogenetic explanation for long-term major biliary

symptoms after endoscopic-sphincterotomy. Endoscopy 1996;28:642-646

11.- Llovet JM, Rodriguez-Iglesias P, Moitinho E, Planas R, Bataller R, Navasa M, Menacho M,

Pardo A, Castells A, Cabré E, Arroyo V, Gasull MA, Rodés J. Spontaneous bacterial peritonitis

in cirrhotic patients undergoing selective intestinal decontamination. A retrospective study of

229 spontaneous bacterial peritonitis episodes. J Hepatol 1997; 26:88-95.

12.- Bataller R, Nicolás JM, Ginès P, Esteve A, Görbig MN, García-Ramallo E, Pinzani M,

Jiménez W, Ros J, Jiménez W, Thomas A, Arroyo V, Rodés J. Arginine vasopressin induces

contraction and stimulates growth in cultured human hepatic stellate cells. Gastroenterology

1997;113:615-624.

13.- Saló J, Guevara M, Fernández-Esparrach G, Bataller R, Ginès A, Jiménez W, Ginès P,

Rivera F, Arroyo V, Rodés J. Impairment of renal function during moderate physical exercise in

cirrhotic patients with ascites. Relationship with the activity of neurohormonal systems.

Hepatology 1997;25:1338-1342.

4

14.- Saló J, Ginès A, Ginès P, Piera C, Jiménez W, Guevara M, Fernández-Esparrach G, Sort

P, Bataller R, Arroyo V, Rodés J. Effect of therapeutic paracentesis on plasma volume and

transvascular escape rate of albumin in patients with cirrhosis. J Hepatol 1997;27:645-653.

15.- Guevara M, Ginès P, Jiménez W, Sort P, Fernández-Esparrach G, Escorsell A, Bataller

R, Bosch J, Arroyo V, Rivera F, Rodés J. Increased adrenomedullin levels in cirrhosis:

relationship with hemodynamic abnormalities and vasoconstrictor systems. Gastroenterology

1998;114:336-343.

16.- Guevera M, Bru C, Ginès P, Fernández-Esparrach G, Sort P, Bataller R, Jiménez W,

Arroyo V, Rodés J. Increased cerebral resistance in cirrhosis: relationship with renin-

angiotensin and central nervous systems. Hepatology 1998;28:39-44.

17.- Bataller-Sifre R, Bataller R. Aclaramiento de ácido glicocólico en la Enfermedad de

Gilbert. An Med Intern 1998;15:580-583.

18.- Bataller R, Nicolás JM, Ginès P, Görbig MN, García-Ramallo E, Tobías E, Pinzani M,

Lario S, Thomas AT, Arroyo V, Rodés J. Contraction of cultured human stellate cells activated

in culture: a role for voltage-operated calcium channels. J Hepatol 1998; 29:398-408.

19.- Görbig MN, Ginès P, Bataller R, Nicolás JM, Garcia-Ramallo E, Clària J, Arroyo V, Rodés

J. Atrial natriuretic factor inhibits endothelin-induced calcium increase and cell contraction in

human cultured hepatic stellate cells. Hepatology 1999;30:501-509.

20.- Bataller R, Ginès P, Nicolás JM, Görbig MN, Garcia-Ramallo E, Bosch J, Arroyo V, Rodés

J. Angiotensin II induces contraction and proliferation of human hepatic stellate cells.

Gastroenterology 2000;118:1149-1156. .

21.- Titos E, Clària J, Bataller R, Bosch-Mercé M, Ginès P, Jiménez W, Arroyo V, Rivera F,

Rodés J. Mechanisms of increased hepatic cysteinyl-leukotriene production in experimental

cirrhosis. Gastroenterology 2000;119:794-805.

22.- Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerón JM, Bataller R, Mas A,

Navasa M, Arroyo V, Rodés J. Terlipressin plus albumin infusion: an effective and safe therapy

for hepatorenal syndromeHepatorenal syndrome. J Hepatol 2000; 33:43-48.

5

23.- Llovet JM, Moitinho E, Sala M, Bataller R, Rodriguez-Iglesias P, Castells A, Fernandez J,

Planas R, Navasa M, Bruix J, Rodes J. Prevalence and prognostic value of hepatocellular

carcinoma in patients presenting with spontaneous bacterial peritonitis. J Hepatol 2000;

33:423-429.

24.- Nicolás JM, Fernández-Solà J, Fatjó R, Casamitjana R, Bataller R, Sacanella E, Tobías

E, Badía E, Estruch R. Increased circulating leptin levels in chronic alcoholism. Alcohol Clin

Exp Res 2001; 25:83-88.

25.- Fernández-Esparrach G, Sánchez-Fueyo A, Ginès P, Uriz J, Quinto L, Ventura PJ,

Cardenas A, Guevara M, Sort P, Jiménez W, Bataller R, Arroyo V, Rodés J. A prognostic

model for predicting survival in cirrhosis with ascites. J Hepatol 2001;34:46-52.

26.- Görbig MN, Ginès P, Bataller R, Nicolás JM, García-Ramallo E, Cejudo P, Sancho-Bru P,

Jiménez W, Arroyo V, Rodés J. Human hepatic stellate cells secrete adrenomedullin: potential

autocrine factor in the regulation of cell contractility. J Hepatol 2001; 34:222-229.

27.- Bataller R, Gasull X, Ginès P, Hellemans K, Görbig MN, Nicolás JM, Sancho-Bru P, De

las Heras D, Gual A, Geerts A, Arroyo V, Rodés J. In vitro and in vivo activation of rat hepatic

stellate cells results in de novo expression of L-type voltage-operated calcium channels.

Hepatology 2001; 33:956-962.

28.- Gasull X, Bataller R, Ginès P, Sancho-Bru P, Nicolás JM, Görbig MN, Ferrer E, Badía E,

Gual A, Arroyo V, Rodés J. Human myofibroblastic hepatic stellate cells express Ca2+-

activated K+ channels that modulate the effects of endothelin-1 and nitric oxide. J Hepatol

2001;35:739-748.

29.- Uriz J, Gines P, Ortega R, Jimenez W, Cardenas A, Calahorra B, Sort P, Fernandez J,

Bataller R, Arroyo V, Rivera F, Rodes J. Increased plasma levels of neuropeptide Y in

hepatorenal syndrome. J Hepatol 2002;36:349-55.

30.- Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, Guevara M,

Bataller R, Jiménez W, Arroyo V, Rodés J. Terlipressin therapy with and without albumin for

patients with hepatorenal syndrome: Results of a prospective, nonrandomized study.

Hepatology 2002;36:941-948.

6

31.- Paik YH, Schwabe R, Bataller R, Russo MP, Jobin C, Brenner DA. Toll-like receptor 4

mediates inflammatory effects by bacterial lipopolysaccharide in activated human hepatic

stellate cells. Hepatology 2003;37:1043-1055.

32.- Bataller R, Ginès P, Sancho-Bru P, Lora JM, Al-Garawi A, Solé M, Nicolás JM, Jiménez

JM, Weich N, Gutierrez-Ramos JC, Arroyo V, Rodés J. Activated human hepatic stellate cells

express the components of the renin-angiotensin system and synthesize angiotensin II.

Gastroenterology 2003;125:117-125.

33.- De las Heras D, Fernandez J, Gines P, Cardenas A, Ortega R, Navasa M, Barbera JA,

Calahorra B, Guevara M, Bataller R, Jimenez W, Arroyo V, Rodes J. Increased carbon

monoxide production in patients with cirrhosis with and without spontaneous bacterial

peritonitis. Hepatology 2003;38:452-459.

34.- Bataller R, Gabele E, Ling Y, Schoonhoven R, Brenner DA, Rippe RA. Prolonged infusion

of angiotensin II into normal rats induces hepatic stellate cells activation and proinflammatory

events in the liver. Am J Physiol 2003; 285:G642-G651.

35.- Bataller R, Schwabe RF, Choi YH, Yang L, Paik YH, Lindquist J, Qian T, Schoonhoven R,

Hagedorn CH, Lemasters JJ, Brenner DA. NADPH oxidase signal transduces angiotensin II in

hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 2003;112:1383-1394.

36.- Schwabe RF, Bataller R, Brenner DA. Human hepatic stellate cells express CCR5 and

RANTES to induce proliferation and migration. Am J Physiol 2003;285:G949-G958.

37.- Stefanovic B, Stefanovic L, Schnabl B, Bataller R, Brenner DA. TRAM2 protein interacts

with endoplasmic reticulum Ca++

pump SERCA 2b and is necessary for collagen type I

synthesis. Mol Cell Biol 2004;24:1758-1768.

38.- Bataller R, Paik YH, Lindquist JN, Lemasters JJ, Brenner DA. Hepatitis C virus core and

nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology

2004;126:529-540.

7

39.- Magness ST, Bataller R, Yang L, Brenner DA. A dual reporter gene transgenic mouse

demonstrates heterogeneity in hepatic fibrogenic cell populations. Hepatology 2004;40:1151-

1159.

40.- Gabele E, Reif S, Tsukada S, Bataller R, Yata Y, Morris T, Schrum LW, Rippe RA. The

role of p70S6K in hepatic stellate cell collagen gene expression and cell proliferation. J Biol

Chem 2005;280:13374-13382.

41.- Bataller R, Gabele E, Parsons CJ, Morris T, Yang L, Schoonhoven R, Brenner DA, Rippe

RA. Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct ligated rats.

Hepatology 2005; 41:1046-1055.

42.- Yang L, Bataller R, Dulyx J, Coffman TM, Rippe RA, Ginès P, Brenner DA. Attenuated

hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice. J Hepatol 2005

43:317-323.

43.- Sancho-Bru P, Bataller R, Gasull X, Colmenero J, Khurdayan V, Gual A, Nicolás JM,

Arroyo V, Rodés V. Genomic and functional characterization of stellate cells isolated from

human cirrhotic livers. J Hepatol 2005;43:272-282.

44.- Yang L, Magness ST, Bataller R, Rippe RA, Brenner DA. NF-kB activation in Kupffer cells

after partial hepatectomy. Am J Physiol Gastrointest Liver Physiol. 2005;289:G530-8.

45.- Sancho-Bru P, Bataller R, Colmenero J, Gasull X, Moreno M, Arroyo V, Brenner DA,

Ginès P. Norepinephrine induces calcium spikes and proinflammatory actions in human hepatic

stellate cells. Am J Physiol Gastrointest Liver Physiol 2006;291:G877-G884.

46.- Bertolami C, Sancho-Bru P, Failli P, Bataller R, Aleffi S, DeFranco R, Mazzinghi B,

Romagnani P, Milani S, Ginès P, Colmenero J, Parola M, Gelmini S, Tarquini R, Laffi G,

Pinzani M, Marra F. Resistin as an intrahepatic cytokine: overexpression during chronic injury

and induction of pro-inflammatory actions in hepatic stellate cells . Am J Pathol 2006;169:2042-

2053.

47.- Colmenero J, Bataller R, Sancho-Bru P, Bellot P, Miquel R, Moreno M, Bosch J, Arroyo V,

Caballería J, Ginès P. Hepatic Expression of Candidate Genes in Patients with Alcoholic

Hepatitis: correlation with Disease Severity. Gastroenterology 2007; 132:687-697.

8

48.- Fatjó F, Sancho-Bru P, Fernández-Solà J, Sacanella E, Estruch R, Bataller R, Nicolás JM.

Up-Regulation of Myocardial L-Type Ca(2+) Channel in Chronic Alcoholic Subjects Without

Cardiomyopathy. Alcohol Clin Exp Res 2007;31:1099-1105.

48.- Cisneros L, Londoño MC, Blasco C, Bataller R, Miquel R, Bruguera M, Ginès P, Rimola A.

Hepatic stellate cell activation in liver transplant patients with hepatitis C recurrence and in non-

transplanted patients with chronic hepatitis C. Liver Transpl 2007;13:1017-1027.

49.- Sancho-Bru P, Bataller R, Fernandez-Varo G, Moreno M, Ármalo LN, Colmenero J, Marí

M, Joan Clària J, Jiménez J, Arroyo V, Brenner DA, Ginès P. Bradykinin attenuates

hepatocellular damage and fibrosis in rats with chronic liver injury. Gastroenterology

2007;133(6):2019-2028.

50.- Rodríguez-Vilarrupla A, Graupera M, Matei V, Bataller R, Abraldes JG, Bosch J, García-

Pagán JC. Large-conductance calcium-activated potassium channels modulate vascular tone

in experimental cirrhosis. Liver Int. 2008;28:566-573.

51.- Botella-Lopez A, de Madaria E, Jover R, Bataller R, Sancho-Bru P, Candela A, Compañ

A, Pérez-Mateo M, Martinez S, Sáez-Valero J. Reelin is overexpressed in the liver and plasma

of bile duct ligated rats and its levels and glycosylation are altered in plasma of humans with

cirrhosis. Int J Biochem Cell Biol 2008;40:766-75.

52.- Domínguez M, Rincón D, González-Abraldes J, Miquel R, Colmenero J, Bellot P, García-

Pagan JC, Fernández-Caspistrán R, Moreno M, Bañares R, Arroyo V, Caballería J, Ginès P,

Bataller R. A new scoring system allows prognostic stratification in patients with alcoholic

hepatitis. Am J Gastroenterol 2008;103:2747-56

53.- Moreno M, Ramalho LN, Sancho-Bru P, Ruiz-Ortega M, Ramalho F, Abraldes JG,

Colmenero J, Dominguez M, Egido J, Arroyo V, Ginès P, Bataller R. Atorvastatin attenuates

angiotensin II-induced inflammatory and pro-fibrogenic actions in the liver. Am J Physiol

2009;296:G147-56.

54.- Ferré N, Martínez-Clemente M, López-Parra M, González-Périz A, Horrillo R, Planagumà

A, Camps J, Joven J, Tres A, Guardiola F, Bataller R, Arroyo V, Clària J. Increased

9

susceptibility to exacerbated liver injury in hypercholesterolemic ApoE-deficient mice: potential

involvement of oxysterols. Am J Physiol Gastrointest Liver Physiol 2009;296:G553-62.

55.- Domínguez M, Miquel R, Colmenero J, Moreno M, García-Pagán JC, Bosch J, Arroyo V,

Gines P, Caballeria J, Bataller R. Hepatic expression of CXC chemokines influence survival

and portal hypertension in patients with alcoholic hepatitis. Gastroenterology 2009;136:1639-

50.

56.- Oakley F, Teoh V, Ching-A-Sue G, Bataller R, Colmenero J, Jonsson JR, Eliopoulos AG,

Watson MR, Manas D, Mann DA. Angiotensin II activates IkappaB kinase phosphorylation of

RelA at Ser536 to promote myofibroblast survival and liver fibrosis. Gastroenterology

2009;136:2334-2344.

57.- Colmenero J, Bataller R, Sancho-Bru P, Dominguez M, Moreno M, Forns X, Bruguera M,

Arroyo V, Brenner DA, Ginès P. Effects of Losartan on Hepatic Expression of Non-phagocytic

NADPH Oxidase and Fibrogenic Genes in Patients with Chronic Hepatitis C. Am J Physiol

Gastrointest Liver Physiol 2009 297:G726-34.

58.- Kluwe J, Pradere JP, Gwak GY, Mencin A, De Minicis S, Osterreicher CH, Colmenero J,

Bataller R, Schwabe RF. Modulation of Hepatic Fibrosis by c-Jun-N-terminal Kinase Inhibition.


59.- Moreno M, Gonzalo T, Kok RJ, Sancho-Bru P, van Beuge M, Swart J, Prakash J,

Temming K, Fondevila C, Beljaars L, Lacombe M, van der Hoeven P, Arroyo V, Poelstra K,

Brenner DA, Ginès P, Bataller R. Reduction of advanced liver fibrosis by targeted delivery of

an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology 2010;51:942-52.

60.- Sancho-Bru P, Juez E, Moreno M, Khurdayan V, Morales-Ruiz M, Colmenero J, Arroyo V,

Brenner DA, Ginès G, Bataller R. Hepatocarcinoma cells stimulate growth, migration and

expression of pro-angiogenic genes in human hepatic stellate cells. Liver International

2010;30:31-41.

61.- Moreno M, Chaves JF, Sancho-Bru P, Ramalho F, Ramalho LN, Mansego ML, Ivorra C,

Dominguez M, Conde L, Millán C, Marí M, Colmenero J, Lozano JJ, Jares P, Vidal J, Forns X,

Arroyo V, Caballería J, Ginès P, Bataller R. Ghrelin attenuates hepatocellular injury and liver

10

fibrogenesis in rodents and influences fibrosis progression in humans. Hepatology

2010;51:974-85.

62.- Azzalini L, Ferrer E, Ramalho LN, Moreno M, Domínguez M, Colmenero J, Peinado VI,

Barberà JA, Arroyo V, Ginès P, Caballería J, Bataller R. Cigarette smoking exacerbates non-

alcoholic fatty liver disease in obese rats. Hepatology 2010;51:1567-76.

63.- Albillos A, Nieto M, Ubeda M, Muñoz L, Fraile B, Reyes E, Lledó L, Blanco I, Pastor O,

Salas C, Lario M, Monserrat J, Bataller R, Álvarez-Mon M. The biological response modifier

AM3 attenuates the inflammatory cell response and hepatic fibrosis in rats with biliary cirrhosis.

Gut 2010;59:943-52.

64.- Moles A, Tarrats N, Morales A, Domínguez M, Bataller R, Caballería J, García-Ruiz C,

Fernández-Checa JC, Marí M. Acidic sphingomyelinase controls hepatic stellate cell activation

and in vivo liver fibrogenesis. Am J Pathol 2010;177:1214-24.

65.- Ki SH, Park O, Zheng M, Kolls J, Morales-Ibanez O, Bataller R, Gao B. Interleukin-22

treatment ameliorates alcoholic liver injury in a murine model of chronic plus binge ethanol

feeding: Role of STAT3. Hepatology 2010;52:1291-300.

66.- Melgar-Lesmes P, Casals G, Pauta M, Ros J, Reichenbach V, Bataller R, Morales-Ruiz M,

Jimenez W. Apelin mediates the induction of profibrogenic genes in human hepatic stellate

cells. Endocrinology 2010;151:5306-14.

67.- Steenkiste CV, Ribera J, Geerts A, Pauta M, Tugues S, Casteleyn C, Libbrecht L, Olievier

K, Schroyen B, Reynaert H, van Grunsven LA, Blomme B, Coulon S, Heindryckx F, De Vos M,

Stassen JM, Vinckier S, Altamirano J, Bataller R, Carmeliet P, Van Vlierberghe H, Colle I,

Morales-Ruiz M. Inhibition of placental growth factor activity reduces the severity of fibrosis,

inflammation, and portal hypertension in cirrhotic mice. Hepatology 2011;53:1629-40.

68.- Altamirano J, Higuera-de laTijera F, Duarte-Rojo A, Martínez-Vázquez MA, Abraldes JG,

Herrera-Jimenez LE, Michelena J, Zapata L, Perez-Hernández J, Torre A, Gonzáles-González

JA, Dominguez M, Arroyo V, Gines P, Caballería J, Bataller R. The amount of alcohol

consumption negatively impacts short-term mortality in hispanic patients with alcoholic

hepatitis. Am J Gastroenterol 2011;106:1472-80.

11

69.- Melgar-Lesmes P, Pauta M, Reichenbach V, Casals G, Ros J, Bataller R, Morales-Ruiz M,

Jiménez W. Hypoxia and proinflammatory factors upregulate apelin receptor expression in

human stellate cells and hepatocytes. Gut 2011;60:1404-11.

70.- Altamirano J, Fagundes C, Dominguez M, García E, Michelena J, Cárdenas A, Guevara M,

Pereira G, Torres-Vigil K, Arroyo V, Caballería J, Ginès P, Bataller R. Acute kidney injury is an

early predictor of mortality for patients with alcoholic hepatitis. Clin Gastroenterol Hepatol

2012;10:65-71.

71.- Altamirano J, Bataller R, Cardenas A, Michelena J, Freixa N, Monrás M, Ríos J, Liccioni

A, Caballería J, Gual A, Lligoña A. Predictive factors of abstinence in patients undergoing liver

transplantation for alcoholic liver disease. Ann Hepatol 2012;11:213-21.

72.- Liu J, Zhou L, Xiong K, Godlewski G, Mukhopadhyay B, Tam J, Yin S, Gao P, Shan X,

Pickel J, Bataller R, O'hare J, Scherer T, Buettner C, Kunos G. Hepatic Cannabinoid Receptor-

1 Mediates Diet-Induced Insulin Resistance via Inhibition of Insulin Signaling and Clearance in

Mice. Gastroenterology 2012;142:1218-28.

73.- Sancho-Bru P, Altamirano J, Rodrigo-Torres D, Coll M, Millán C, José Lozano J, Miquel R,

Arroyo V, Caballería J, Ginès P, Bataller R. Liver progenitor cell markers correlate with liver

damage and predict short-term mortality in patients with alcoholic hepatitis. Hepatology 2012

(in press).

74.- Affo, S, Dominguez M, Lozano JJ, Sancho-Bru P, Rodrigo-Torres D, Morales-Ibanez O,

Moreno M, Millan C, Loaeza-del-Castillo A, Altamirano J, Garcia-Pagan JC, Arroyo V, Gines P,

Caballeria J, Bataller R. Transcriptome Analysis Identifies Fn14, a TNF Superfamily Receptor,

as a Therapeutic Target in Alcoholic Hepatitis. Gut 2012 (in press).

Case reports:

1.- Bataller-Sifre R, Peydró A, Arroyo M, Bataller R, Carda C, Broseta R. Determinación de

cobre en tejido hepático para el diagnóstico de la Enfermedad de Wilson. An Med Intern 1989;

6 :145-148.

12

2.- Sierra J, Martí JM, Bataller R, Calvet X, Bru C, Grañena A, Rozman C. Pancreatic

pseudocyst secondary to chemotherapy for acute lymphoblastic leukaemia: successful

percutaneous drainage. Eur J Med 1992; 1:36-371.

3.- Morell M, Ordi J, Bataller R, Trias M, Cardesa A. Pneumatosis cystoides intestinalis en una

paciente con enfermedad de Crohn. Gastroenterol Hepatol 1993;16:67-69.

4.- Elizalde JI, Escorsell A, García-Pugués A, Navarro S, Bataller R, Terés J. Sarcoma de

Kaposi de localización rectal aislada. Rev Esp Enf Digest 1993; 84:399-401.

5.- Bataller R, Urbano-Izpizua A, Luburich P, Monserrat E, Rozman C. Masa pulmonar

cavitada como manifestación inicial de la enfermedad de Hodgkin. Med Clin (Barcelona) 1994;

103:342-343.

6.- Elizalde JI, Bataller R, Bruix J, Rodés J. Hepatotoxicidad por propafenona. Gastroenterol

Hepatol 1994; 18(8):382-383.

7.- Bataller R, Bordas JM, Ordi J, Llach J, Elizalde JI, Mondelo F. Upper Gastrointestinal

bleeding: a complication of “inlet patch mucosa” in the upper esophagus. Endoscopy 1995;

27:282-283.

8.- Sánchez A, Bataller R, Ginés A, Bruguera M, Rodés J. Tumor carcinoide con afectación

masiva hepática sin síndrome carcinoide asociado. Gastroenterol Hepatol 1995; 18:468-470.

9.- Andreu V, Bataller R, Caballería J, Rodés J. Eosinophilic pneumonitis due to ranitidine. J

Clin Gastroenterol 1996; 23: 160-162.

10.- López-Boado MA, Rull R, Bataller R, González FX, Bordas JM, Visa J. Neumoperitoneo

asintomático después de una fibrogastroscopia. Rev Esp Enf Digest 1996; 88: 365-367.

11.- Bataller-Sifre R, Vicente R, Llombart A, Carda C, Gabriel F, Bataller R, Galindo J. Déficit

heterozigótico de alfa-1 antitripsina. Presentación de un caso. Gastroenterol Hepatol 1996; 19:

313-316.

13

12.- Bataller R, Salmerón JM, Muñoz JE, Obach V, Elizalde JI, Mas A, Tolosa E, Terés J.

Estenosis pilórica complicada con el síndrome de Wernicke-Korsakoff. Gastroenterol Hepatol

1997; 20: 131-133.

13.- Bataller R, Sans M, Escorsell A, Elizalde JI, Bosch J, Rodés J. Esophageal variceal

bleeding due to hypoplasia of the portal vein in a patient with the Klippel-Trenaunay syndrome.

Am J Gastroenterol 1998; 93: 275-276.

14.- Bataller R, Bragulat E, Nogué S, Görbig MN, Bruguera M, Rodés J. Prolonged cholestasis

due to paraquat poisoning throught skin absorption. Am J Gastroenterol 2000;95:1340-1343.

15.- Altamirano J, Zapata L, Poblano M, Rodríguez A, Camargo L, Martínez B, Bataller R.

Acute pylephlebitis following gastrointestinal infection: an unrecognized cause of septic shock.

South Med J 2010;103:956-959.

16.- Ruiz P, Michelena J, Altamirano J, Miquel R, Moreira L, Cárdenas A, Abraldes JG, Brugera

M, Arroyo V, Ginès P, Caballería J, Bataller R. Hepatic hemodynamics and transient

elastography in alcoholic foamy degeneration: report of 2 cases. Ann Hepatol 2012;11:399-403.

Reviews and editorials:

1.- Bataller Sifre R, Gómez García M, Bataller RB, Bataller R, Alberola García MD. Replicación

viral, daño histológico y movimiento enzimático en hepatopatías crónicas por virus B. Rev Esp

Enf Digest 1989; 75:620-624.

2.- Bataller Sifre R, Bataller R, Baleriola Júlvez J. Hepatomegalia. Medicine (Madrid) 1993;

6:325-330.

3.- Bordas JM, Nieto I, Llach J, Mondelo F, Elizalde I, Bataller R, Landaeta J, Terés J. La

endoscopia digestiva en el síndrome de inmunodeficiencia adquirida. Cir Laparosc Endosc

1994; 1:43-47.

4.- Bataller R. Actitud ante la colestasis crónica. Jano 1995;23:34-37.

5.- Bataller R. Anomalías de la función renal en la cirrosis. Medicine (Madrid) 1996; 7:439-444.

14

6.- Bataller R. Cirrosis hepática: clasificación etiopatogénica, valoración funcional y factores

pronósticos. Medicine (Madrid) 1996; 7:421-426.

7.- Bataller R. La collaborazione scientifica nella Cominutà Europea. Fondazione Italiana per lo

Studio del Fegato 1996: 22-23.

8.- Bataller R. Ascitis. Protocolo terapéutico. Fomeco 1996; 4:208-216.

9.- Bataller R, Ginès P, Arroyo V. Practical recommendations for the treatment of ascites and

its complications. Drugs 1997; 54:571-580.

10.- Bataller R, Ginès P, Guevara M, Arroyo V. Hepatorenal Syndrome. Semin Liver Dis 1997;

17:233-247.

11.- Bataller R, Arroyo V, Ginès P. Management of ascites in cirrhosis. Gastroenterol Hepatol

1997; 12:723-733.

12.- Bustamante J, Bataller R, Sánchez-Fueyo A. Diagnóstico de la Enfermedad de Wilson.

Gastroenterol Hepatol 1997; 20:510-513.

13.- Bataller R, Arroyo V, Ginès P. Hepatorenal syndrome: definition, pathophysiology, clinical

features and management. Kidney Int 1998; 66:S47-53.

14. Bataller R, Ginès P, Arroyo V, Sort P. The hepatorenal syndrome. Forum (Genova) 1998;

8:62-81.

15.- Planas R, Bataller R, Rodés J. Hepatorenal syndrome. Current Treatment Options in

Gastroenterology. 2000; 3:445-450.

16.- Bataller R, Ginès P, Arroyo V, Rodés J. Hepatorenal syndrome. Clin Liver Dis 2000;4:487-

507.

17.- Cárdenas A, Bataller R, Arroyo V. Mechanisms of ascites formation. Clin Liver Dis

2000;4:447-465.

15

18.- Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis.

Semin Liver Dis 2001;21:437-451.

19.- Bataller R, Ginès P. Nuevas perspectivas terapeúticas en la fibrosis hepática: bases

patogénicas. Med Clin (Barc) 2002;118:339-346.

20.- Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver

fibrosis: a critical appraisal. Hepatology 2003;37:493-503.

21.- Bataller R. Los polimorfismos genéticos y las enfermedades del hígado. Gastroenterol y

Hepatol 2003;26:307-309.

22. Forns X, Bataller R. Can we identify liver fibrosis in HCV-infected patients without a liver

biopsy? Current Hepatitis Reports 2003:2:145-151.

23.- Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-218.

24.- Bataller R, Sancho-Bru P, Ginès P, Brenner DA. Liver fibrosis: a new role for the renin-

angiotensin system. Antioxidant Redox Signal 2005:7:1346-1355.

25.- Schnabl B, Choi YH, Hagedorn CH, Bataller R. DNA microarrays and data mining to study

hepatic fibrosis. Methods Mol Med 2005;117:359-70.

26.- De Minicis S, Bataller R, Brenner DA. NADPH oxidase in the liver: defensive, offensive, or

fibrogenic? Gastroenterology 2006;131:272-275.

27.- Bataller R. Time to ban smoking in patients with chronic liver diseases. Hepatology

2006;44:1394-1346.

28.- Moreno M, Bataller R. Cytokines and Renin-Angiotensin system signaling in hepatic

fibrosis. Clin Liver Dis 2008;12:825-52.

29.- Lligoña A, Freixa N, Bataller R, Monràs M, Rimola A. Clinical guideline for the evaluation

of liver transplant candidates with addictions. Gastroenterol Hepatol 2009;32:155-61.

30.- Altamirano J, Bataller R. Cigarette smoking and chronic liver diseases. Gut 2010;59:1159-

16

1162.

31.- Morales-Ibanez O, Bataller R. Platelet-derived chemokines: new targets to treat liver

fibrosis ? J Hepatol 2011;54:581-3.

32.- Bataller R, Rombouts K, Altamirano J, Marra F. Fibrosis in alcoholic and nonalcoholic

steatohepatitis. Best Pract Res Clin Gastroenterol 2011;25:231-44.

33.- Affó S, Bataller R. RANTES Antagonism: a Promising Approach to Treat Chronic Liver

Diseases. J Hepatol 2011;55:936-8.

34.- Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets.


35.- Altamirano J, Bataller R. Alcoholic liver disease: pathogenesis and new targets for

therapy. Nat Rev Gastroenterol Hepatol 2011;8:491-501.

Books

1.- Bataller R, Caballería J (eds). Non Alcoholic Steatohepatitis. Permanyer Publications,

Barcelona, 2007.

Book chapters:

1.- Bataller R, Arroyo V. Tratamiento de la ascitis. In: Esplugues JM, Piqué JM, Ponce J (eds).

Terapéutica Farmacológica de las Enfermedades del Aparato Digestivo. 1st edition. Eunsa,

Pamplona, 1996:275-286.

2.- Arroyo V, Bataller R. Treatment of hepatorenal Syndrome. In: Arroyo V, Ginès P, Rodés J,

Schirer RW (eds). Ascites and Renal Dysfunction in Liver Disease. Blackwell Science, Malden,

1999:3-14.

4.- Arroyo V, Bataller R. Historical notes on ascites. In: Arroyo V, Ginès P, Rodés J, Schirer

RW (eds). Ascites and Renal Dysfunction in Liver Disease. Blackwell Science, Malden, 1999:3-

14.

17

5.- Bataller R, Uriz J. Spontaneous circulatory failure in cirrhosis. Mechanisms and

consequences. In: Arroyo V, et al (eds). Therapy in Liver Diseases, 3th Edition. Masson,

Barcelona, 1999:147-154.

6.- Cárdenas A, Bataller R, Arroyo V. Mechanisms of ascites formation. In: Clinics in Liver

Disease. J.L.Herven. W.B. Saunders Co. Philadelphia 2000:447-466.

7.- Bataller R, Arroyo V. Fracaso renal agudo asociado a enfermedades hepáticas. Síndrome

hepatorenal. In Liaño F, Pascual J. Fracaso renal agudo. Barcelona. Masson. 2000: 103-

125:313-326

8.- Bataller R, Ginés P, Arroyo V, Rodés J. Hepatorenal syndrome. In: Clinics in Liver Disease.

W.B. Saunders Co. Philadelphia 2000:487-508.

9.- Arroyo V, Bataller R, Ginès P. Ascites and spontaneous Bacterial Peritonitis. In:

Comprehensive Clinical Hepatology. J. O. Grady, J.R. Lake, P.D. Howdle (eds). Mosby. Saint

Louis 2000:7/1-7/14.

10.- Uriz J, Bataller R, Arroyo V. Síndrome Hepatorenal. In: Lovesio C (ed). Medicina

Intensiva. Editorial el Ateneo. Buenos Aires 2001;634-640.

11.- Arroyo V, Cárdenas A, Bataller R. Ascites and spontaneous bacterial peritonitis. In:

Gastroenterologija I Hepatologija. Volume 2. Boris Vucelic I Suradnici (ed). Medicinska

Anclada. Zagreb, 2002:1302-1314.

12.- Arroyo V, Cárdenas A, Bataller R. Renal Complications in Liver DiseaseAscites and

Spontaneous Bacterial Peritonitis. In: Gastroenterologija I Hepatologija. Volume 2. Boris

Vucelic i Suradnici (ed). Medicinska Anclada. Zagreb, 2002:1294-1301.

13.- Bataller R, Sancho-Bru P, Ginès P. The renin-angiotensin system and liver fibrosis:

therapeutical implications. In: Arroyo V, Forns X, García-Pagán JC, Rodés J. Progress in the

Treatment of Liver Diseases. Arts Medica, Barcelona 2003:209-214.

14.- Bataller R, Arroyo V. Ascites. Non-operative management. In: Controversies in Surgery.

Volume 4. Springer-Verlag. Heildelberg 2004.

18

15.- Bataller R, Colmenero J, Sancho-Bru P. Etiology and Pathogenesis. In: Navasa M, Arroyo

V (eds). Liver cirrhosis. Doyma, Barcelona 2005.

16.- Bataller R, Domínguez M, Caballería J. Clinical manifestations and prognosis of NASH. In:

Bataller R, Caballería J (eds). Non Alcoholic Steatohepatitis. Permanyer Publications,

Barcelona, 2007.

17.- Bataller R, Brenner DA. Pathogenesis of Hepatic Fibrosis. In: Yamada T, Alpers DH,

Kaplowitz N, Owyang C, Powell DW, Kalloo A (eds). Textbook of Gastroenterology, 5th Edition,

Blackwell Publishing, Oxford England 2007.

18.- Bataller R, Sancho-Bru P. New therapeutical approaches in Hepatology. En: Arroyo V,

Sánchez-Fueto A, Fernández-Gómez J et al et al. Advances in the Therapy of Liver Diseases.

Ars Medica, Barcelona, 2007, 515-522.

19.- Bataller R, Brenner DA. Liver Fibrosis. In: Arias IM, Wolkoff A, Fausto N, Boyer JM,

Shafritz D, Alter H (eds). The Liver: Biology and Pathobiology. Wiley-Blackwell, 2009.

Invited lectures.

1.- Presentación de casos clínicos de Hepatología. III Curso Iberoamericano de Hepatología.

Barcelona, Spain, 1996.

2.- Presentación de casos clínicos de Hepatología. IV Curso Iberoamericano de Hepatología.


3.- "Papel de las células estrelladas hepáticas en la patogenia de la hipertensión portal". VII

Curso de Hepatología, Hospital Reina Sofía. Córdoba, Spain, 1999.

4.- "Spontaneous circulatory dysfunction in cirrhosis. Pathogenesis and consequences", 3rd

International Meeting on Therapy in Liver Diseases. Barcelona, Spain,1999.

5.- “Hepatopatía alcohólica: nuevos avances en la patogenia y tratamiento”. Reunión de la

Sociedad de Gastroenterología de Jalisco, Guadalajara, México, 2000.

6.- “Liver transplantation and hepatic fibrosis”. Transplant Course. University of North Carolina

at Chapel Hill, Chapel Hill, NC, USA, 2002.

19

7.- “Patogenia y tratamiento de la fibrosis hepatica”. Curso de la Asociación Mexicana de

Hepatología, Querétaro, México, 2003.

8.- “Role of the renin-angiotensin system in liver fibrosis”. Meeting on Inflammation and Fibrosis

in the Bowel and the Liver. Chapel Hill, USA, 2003.

9.- “Vasoactive substances: RAS inhibitors”. XXVII Meeting of the European Association of

Gastroenterology. Madrid, Spain, 2003.

10.- “Liver fibrosis in chronic hepatitis C: pathogenesis and treatment”. Frontiers in Hepatology,

Pamplona, Spain, 2003.

11.- “Patogènia i tractament del NASH”. Col.legi de Metges, Barcelona, Spain, 2003.

12.- “NASH: pathogenesis and current therapy”. New Treatments on Obesity, Hospital Clinic,


13.- “Hepatitis C y fibrosis hepática”. II Curso de Hepatología del Hospital de Sant Pau.


14. “Síndrome metabólico y fibrosis hepática”. Cursos de Doctorado, Universitat de Valencia,

Spain, 2005.

15. “Fibrosis hepatica”. LXIV Congreso Anual de la Sociedad Española de Patología Digestiva,

Madrid, Spain, 2005.

16.- “Liver fibrogenesis: pathogenesis and new targets for therapy”. University of Florence,

Italy, 2005.

17.- “Ion fluxes, channels and transporters”. EASL Course in Basic Science, Toscany, Italy,

2006.

18.- “The angiotensinogen pathway”. AASLD Single Topic Conference on Liver Fibrosis.

Washington, 2006.

20

19.- “Role of the Renin-Angiotensin System in Liver Fibrosis”. Brisbane, Australia, 2006.

20. “Fibrosis hepática”. Cursos de Doctorado, Hospital Gregorio Marañón, Spain, 2006.

21.- “Pathogenesis of alcohol-induced liver fibrosis: prospects for therapy”. Sydney, Australia,

2006.

22.- “Renin-angiotensin system signaling and liver fibrosis”. EASL School of Medicine, Lisbon,

Portugal, 2006.

23.- “Liver fibrosis: genetic tests”. 14th United European Gastroenterology Week, Berlin,

Germany, 2006.

24.- “Fibrosis hepática: una respuesta regenerativa patológica en las hepatopatías crónicas”.

Real Academia de farmacia, Madrid, Spain, 2006.

25.- “Fisiopatología y tratamiento de la fibrosis hepática”. I Curso de Hepatología. Hospital

Clínic, Barcelona, Spain, 2006.

26.- “Nuevas perspectives terapéuticas en la fibrosis hepática”. Pamplona, Spain, 2007.

27.- “Non-invasive diagnosis of hepatic fibrosis”. Curso conjunto AGA-SEPG, Madrid, Spain,

2007.

28.- “Fibrosis hepática; fisiopatología y tratamiento”. II Curso de Hepatología. Hospital Clínic,


29.- “Futuros tratamientos en hepatología: células madre y farmacogenómica”. Sevilla, Spain,

2007.

30.- “Fibrosis hepática: bases genéticas y nuevas perspectivas terapéuticas”. Santiago de

Chile, Chile, 2007.

31.- “New therapies in hepatology”. V Meeting on Therapies of Liver Diseases, Barcelona,

Spain, 2007.

21

32.- “Pathogenesis of fibrosis in chronic liver diseases”. EASL School of Medicine. Barcelona,

Spain, 2007.

33.- “Fibrosi hepàtica: patogènia, diagnostic no invasiu i noves perspectives terapèutiques”.

Acadèmia de Medicina de Catalunya, Barcelona, Spain, 2008.

34.- “Fibrosis hepática; patogenia y tratamiento”. III Curso de Hepatología. Hospital Clínic,


35.- “Mechasnismos and genetics”. V International Meeting on Immunology and the Liver:

Fibrosis-Mechanisms and Therapies. Madrid 2009.

36.- “Tratamiento de la fibrosis hepática”. XXXIV Congreso de la Asociación Española para el

Estudio de las Enfermedades del Hígado. Madrid, 2009.

37.- “Reactive oxygen species and liver fibrosis”. 19th Conference of APASL, Hong Kong, 2009. 38.- “Recomendaciones actuales para el diagnóstico y tratamiento de la fibrosis hepática”. Actualizaciones en Hepatología, Aranjuez, Spain, 2009. 39.- ”Alcoholic hepatitis: identification of new targets for therapy”. University of Regensburg, Germany, 2009. 40.- “Experimental Liver Fibrosis”. University of Sao Paolo at Riberio Preto, Brazil 2010. 41.- “Towards the translation of basic research to clinical solutions for fibrosis”. EASL International Liver Meeting. Vienna, Austria, 2010. 42.- “New therapeutic targets for alcoholic hepatitis identified in human samples”. ESBRA-EASL Joint Meeting, Vienna, Austria, 2010. 43.- “How to treat patients with hepatitis C non-responding to antiviral therapy ?” White Night of Hepatology, St Petersburg, Russia, 2010. 44.- ”Alcoholic hepatitis: identification of new targets for therapy”. NIAAA, NIH, Bethesda, 2010. 45.- ”Alcoholic hepatitis: identification of new targets for therapy”. University of California at San Diego, 2010. 46.- “APRI and Fibrotest: critical analysis of pros and cons”. Hepatologia do Milenio, Salvador de Bahia, Brazil, 2010. 47.- “Human and experimental evidence supporting a role for osteopontin in the pathogenesis of alcoholic liver disease”. International Society for Hepatic Sinusoid Research, Pasadena, California, 2010.

22

48.- “Fibrogénesis hepática: mecanismos”. IV Congreso Nacional del Laboratorio Clínico. Zaragoza, Spain, 2010. 49.- “Molecular mechanisms of liver fibrosis”. ISBRA World Congress, Paris, 2010. 50.- “Particular issues in transplantation for alcoholic and metabolic liver diseases”. 18th United European Gastroenterology Week, Barcelona, 2010. 51.- “Alcoholic liver disease: mechanisms”. 18th United European Gastroenterology Week, Barcelona, 2010. 52.- “Alcoholic hepatitis: identification of new targets for therapy. EASL Monothematic Conference: Alcoholic Liver Disease”. Athens, Greece, 2010. 53.- “Genetic markers”. EASL Conference on Evaluation of Disease Severity and Prognosis in Chronic Liver Disease. Nize, France, 2011. 54.- “Non-invasive liver fibrosis assessment”. Early Morning Workshop. EASL Annual Meeting, Berlin, Germany, 2011. 55.- “Alcoholic hepatitis: identification of new targets for therapy”. University of North Carolina at Chapel Hill, USA, 2011. 56.- “Alcoholic Liver Disease”. State-of-the-Art Lecture, Hepatologia do Milenio, Salvador de Bahia, Brazil, 2011. 57.- “Opciones terapéuticas actuales y a futuro de la fibrosis hepática”. Curso de Nutricion, Mexico DF, Mexico, 2012. 58. “Age as a risk factor for accelerated liver fibrosis: potential mechanisms”. Myoage, Barcelona, Spain, 2011. 59.- “Genes and Cirrhosis”. 9th International Meeting on Therapy in Liver Diseases, Barcelona, Spain, 2012. 60.- “Alcoholic Liver Disease: an Update”. University of Arkansas, Little Rock, USA, 2012.

61. “New Therapeutic Targets for Alcoholic Hepatitis”, NIAAA Extramural Meeting on Alcoholic

Hepatitis, Bethesda, NIH, USA, 2012. 62.- “Alcoholic liver disease: novel targets for therapy”. King’s College, London, UK, 2012. 63.- “Concluding remarks: Alcoholic Liver Disease”. Co-director, Postgraduate Course. EASL Anual Meeting, Barcelona 2012.

Awards:

1. "Premio de Ayuda al Estudio". Caja de Ahorros de Alicante.1986.

23

2.- "Beca de Introducción a la Investigación". Consejo Suerior de Investigaciones Científicas.

With the work entitled: "Diferenciación sexual del Sistema Nervioso Central" in the “Instituto de

Neurobiología Ramón y Cajal". Madrid. 1989.

3.- "Beca de Iniciación a la Investigación". Consellería de Cultura, Educació i Ciència de la

Generalitat Valenciana. “Determinación de HBV-DNA en hepatopatías crónicas virales tratadas

con Interferon a 2-recombinante". Valencia. 1990.

4.- “Beca predoctoral”. Consell Interdepartamental de Recerca i Tecnologia de la Generalitat

de Catalunya (CIRIT). Barcelona. 1996-1999.

5.- Beca final Residencia N°1 (Premio Emili Letang). Hospital Clínic of Barcelona. 1994.

6.- Best communication on portal hypertension, 32nd

Annual Meeting of the European

Association for the Study of the Liver. London, 1997. R Bataller, P Ginès N, JM Nicolás, MN

Görbig, E Garcia-Ramallo, M Pinzani, V Arroyo, J Rodés. Human hepatic stellate contain

voltage-operated calcium channels.

7.- Best communication on portal hypertension, 34th Annual Meeting of the European

Association for the Study of the Liver. Napoli, 1999. N Görbig, P Ginès, R Bataller, E Garcia-

Ramallo, J Ros, W Jiménez, JM Nicolás, V Arroyo, J Rodés. Human hepatic stellate cels

release the vasodilator peptide adrenomedullin. Potential autocrine factor in the regulation of

stellate cell contractility.

8.- Best poster presentation, 34th Annual Meeting of the European Association for the Study of

the Liver. Napoli, 1999. R Bataller, P Ginès, X Gasull, MN Görbig, E Garcia-Ramallo, JM

Nicolás, A Gual, V Arroyo, J Rodés. Phenotypic transformation of hepatic stellate cells into

myofibroblasts results in the expression of voltage-operated calcium channels.

9. Premio extraordinario de la Tesis Doctoral, Facultat de Medicina, Universitat de Barcelona,

2000.

10.- “Beca de la Asociación Española para Estudio de las Enfermedades del Hígado” for

postdoctoral stay in USA. Madrid, Spain, 2000-2002.

24

11.- Postdoctoral Research Fellowship Award from the American Liver Foundation.

“Investigation of the cellular and molecular mechanisms of hepatitic C virus-induced liver

fibrosis”. Chapel Hill, NC, USA, 2003.

Grant support:

1.- " ENFERMEDAD HEPÁTICA EN PACIENTES CON CONSUMO DE RIESGO DE ALCOHOL: IDENTIFICACIÓN LOS FACTORES GENÉTICOS Y AMBIENTALES Y DE NUEVAS DIANAS TERAPÉUTICAS". GRANT FROM THE SPANISH MINISTRY OF SCIENCE AND INNOVATION (FIS). PRINCIPAL INVESTIGATOR. 2012-2014. € 312,000. 2.- “HEPATIC MICROFLUIDIC BIOREACTOR (HEMIBIO)”. EUROPEAN UNION (HEALTH-2010-4.2.9-2). CO-INVESTIGATOR. 2011-2014. € 276,801. 3.- ”DEVELOPMENT OF A GENETIC TEST TO PREDICT THE PROGRESSION OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C”. GRANT FROM THE SPANISH MINISTRY OF SCIENCE AND INNOVATION (PET2008_0304). PRINCIPAL INVESTIGATOR. 2009-2011. € 121,000. 4. “INVESTIGACIÓN TRASLACIONAL EN PACIENTES CON HEPATOPATÍAS CRÓNICAS: DESARROLLO DE MÉTODOS PRONÓSTICOS E IDENTIFICACIÓN DE NUEVAS DIANAS TERAPÉUTICAS”. GRANT FROM THE SPANISH MINISTRY OF SCIENCE AND INNOVATION (FIS). PRINCIPAL INVESTIGATOR. 2009-2011. € 135,762. 5. “DEVELOPMENT OF INNOVATIVE ASSAYS AND LOCALLY ACTING THERAPIES AIMING AT CRITICAL KINASES IN HEPATIC AND RENAL FIBROSIS (DIALOK)”. EUROPEAN UNION (FP6-2005-LIFESCIHEALTH-7). INVESTIGATOR. 2006-2009. € 270,000. 6. “CELLULAR AND MOLECULAR MECHANISMS OF HEPATITIS C-INDUCED LIVER FIBROSIS”. GRANT FROM THE SPANISH MINISTRY OF SCIENCE AND INNOVATION (SAF). PRINCIPAL INVESTIGATOR. 2005-2008. € 121.000 7.- “ANGIOTENSIN II AND NADPH OXIDASE IN HEPATIC FIBROSIS”. NIH GRANT (1R01DK072237-01). COLLABORATOR. 2004-2008. 8.- “HEPATIC STELLATE CELL ACTIVATION INDUCED BY HEPATITIS C VIRUS”. NIH GRANT (5 R01 AA015955DK-03-011). CO-INVESTIGATOR. 2003-2007. € 60.000 9.- “CONTRACTILE AND FIBROGENIC FUNCTIONS OF HEPATIS STELLATE CELLS”. GRANT FROM THE SPANISH MINISTRY OF SCIENCE AND INNOVATION (SAF2002-03696). INVESTIGATOR. 2000-2002.

25

10.- “PROINFLAMMATORY AND FIBROGENIC FUNCTIONS OF HEPATIC STELLATE CELLS”. GRANT FROM THE SPANISH MINISTRY OF SCIENCE AND INNOVATION (SAF99-0014). INVESTIGATOR. 1997-1999.

Doctoral thesis:

1.- Sancho-Bru P. “Role of Vasocactive Substances in Hepatic Fibrosis”. 2006.

2.- Domínguez M. “Alcoholic Hepatitis: Pathogenic Basis and Prognostic Factors”. 2009.

3.- Colmenero J. “Gene Expression Analysis for the Ideentification of Therapeutic Targets and

Response to Therapy in Patients with Liver Fibrosis”. 2009.

4.- Moreno M. “Research of Novel Therapies for Liver Inflammation and Fibrosis”. 2010.

curriculum vitae ramón bataller, m.d.sph.unc.edu/files/2013/07/708770519_cv.pdf · endoscópico...

Documents